A previously unreported case of suppurative thrombophlebitis due to Clavispora lusitaniae

Toru Yoneda; Takayuki Hoshina; Tomofumi Fukuda; Nao Ohama; Saori Murakawa; Koichi Kusuhara

doi:10.1016/j.mycmed.2023.101390

A previously unreported case of suppurative thrombophlebitis due to Clavispora lusitaniae

J Mycol Med. 2023 Aug;33(3):101390. doi: 10.1016/j.mycmed.2023.101390. Epub 2023 Apr 21.

Authors

Toru Yoneda¹, Takayuki Hoshina², Tomofumi Fukuda¹, Nao Ohama¹, Saori Murakawa¹, Koichi Kusuhara¹

Affiliations

¹ Department of Pediatrics, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan.
² Department of Pediatrics, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan. Electronic address: hoshina@med.uoeh-u.ac.jp.

PMID: 37126897
DOI: 10.1016/j.mycmed.2023.101390

Abstract

We report a case with Clavispora lusitaniae-induced purulent thrombophlebitis. The patient had multiple risk factors for the development of fungal thrombophlebitis including surgical procedure, mechanical ventilation, admission to intensive care unit, total parenteral nutrition and long-term antimicrobial therapy in addition to the insertion of central venous catheter. The symptoms finally improved by a combination therapy of micafungin and flucytosine, but the therapy did not rapidly resolve candidemia. The appropriate antifungal therapy for C. lusitaniae-induced purulent thrombophlebitis is uncertain. Further study is desired to seek the appropriate therapy for the disease.

Keywords: Catheter-related infections; Clavispora lusitaniae; Flucytosine; Micafungin microbial sensitivity test; Thrombophlebitis.

Publication types

Case Reports

MeSH terms

Antifungal Agents / pharmacology
Antifungal Agents / therapeutic use
Humans
Micafungin
Saccharomycetales*
Thrombophlebitis* / diagnosis
Thrombophlebitis* / drug therapy

Substances

Antifungal Agents
Micafungin

Supplementary concepts

Clavispora lusitaniae